Women’s Cancer Mortality: Why Life Expectancy Gap Exists | Healio

Women experience a survival advantage over men across many causes of death, but this isn’t universally true when it comes to cancer. A fresh analysis, published March 10, 2026, reveals that women born since the 1930s face a consistent disadvantage in cancer mortality, specifically linked to reproductive cancers. This excess mortality effectively narrows the overall life expectancy gap between sexes, and highlights a critical area for targeted public health intervention.

The ‘Price of Reproduction’

The study, led by Vladimir Canudas-Romo, PhD, of The Australian National University, analyzed data from 20 low-mortality countries. Researchers found that women generally live 4 to 8 years longer than men in these nations. However, this gap would be even wider – potentially increasing survival for women by as much as 0.7 years in the U.S. – if not for the impact of breast and gynecologic cancers. The research, published in JAMA Network Open, frames this disparity as the “price of reproduction,” emphasizing the need for increased focus on prevention, early detection, and equitable access to treatment for these cancers.

“We estimate that one half to a full year could be achieved of extra survival for females across those countries if the excess female reproductive cancer mortality disappeared,” Canudas-Romo told Healio.

A Paradoxical Finding

Traditionally, the survival gap between men and women has been attributed to factors like cardiovascular diseases, smoking-related cancers, and accidental deaths, where men typically experience higher rates. However, this analysis points to a different dynamic. “The focus on the gap in survival between females and males is usually on those causes of death where males perform badly: heart attacks, strokes, accidents, suicide, etc.,” Canudas-Romo explained. “The female longevity advantage is true for all causes of death, except in cancers. This prompted us to further explore this paradoxical result.”

The researchers utilized data from the Human Mortality and WHO Mortality databases, encompassing over 264 million deaths – with roughly 55% being male – including 11.5 million deaths attributed to female reproductive malignancies. They employed a method called Truncated cross-sectional average length of life (TCAL), which considers historical data to provide a more comprehensive picture of lifespan.

Country-Specific Disparities

The study revealed significant variations in the sex gap in TCAL across different countries. Japan showed the highest TCAL for women (86.21 years), while Sweden had the highest for men (79.62 years). Hungary exhibited the lowest TCAL for both women (77.85 years) and men (69.54 years). The gap ranged from 4.22 years in the Netherlands to 8.31 years in Hungary.

In the United States, the sex gap in TCAL was 5.38 years. The primary contributors to this gap were cardiovascular diseases (1.75 years), external causes of death (1.47 years), and cancer (0.84 years). However, a closer look revealed that women aged 35 to 60 experienced an “excess” in cancer-related deaths.

Removing breast cancer mortality from the equation would increase the overall TCAL gap related to tumors in the U.S. From 0.84 to 1.26 years. Eliminating gynecologic malignancies would raise it from 0.84 to 1.12 years, and removing both would increase the TCAL sex gap by a full 0.7 years in favor of women. Globally, researchers found that eliminating breast and gynecologic cancers would increase the TCAL gap by an average of 0.77 years, ranging from 0.51 years in Japan to 0.96 years in Ireland.

Implications for Public Health

“We were surprised to see how consistent the female disadvantage respect to men in cancer survival between ages 35 and 60 is across the developed world,” Canudas-Romo stated. This consistency underscores the need for a global approach to addressing this issue.

The researchers acknowledge that their study focused primarily on high-income countries, representing a limitation. “We have now studied this at the national and international level, but there could be groups with greater disadvantage within our populations,” Canudas-Romo added. “The next effort will be to try to identify those groups that need targeted public health interventions to reduce this excess mortality.”

Further research is planned to pinpoint specific populations experiencing the greatest disparities and to develop tailored interventions. The team is actively seeking partner institutions to collaborate on these future efforts. Vladimir Canudas-Romo, PhD, can be reached for further information.

This study highlights the importance of continued surveillance of cancer mortality rates, particularly among women of reproductive age. It also reinforces the need for ongoing investment in research aimed at understanding the underlying causes of these disparities and developing more effective prevention and treatment strategies. Individuals concerned about their risk of reproductive cancers should discuss their concerns with a qualified healthcare professional and stay informed about current screening guidelines. For more information on breast cancer, visit the American Cancer Society or the National Breast Cancer Foundation.